Posts by Peter W. PENG

The 2026 European Hematology Association (EHA) Congress in Stockholm has concluded, unveiling a series of important advances in acute myeloid leukemia (AML). To help clinicians rapidly interpret the meeting's most impactful findings, the inaugural CSCO Leukemia Young Committee Perspectives webinar was held on June 14 through a collaboration between the CSCO Leukemia Youth Committee and Hematology Frontier. The program was chaired by Professor Qiu Shaowei, Chair of the CSCO Leukemia Committee Youth Group from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences (CAMS). Joining the discussion were Professor Pei Shanzhan from the First Affiliated Hospital, Zhejiang University School of Medicine and Liangzhu Laboratory, Professor Tang Feifei from Peking University People's Hospital, and Professor Cao Yigeng from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences (CAMS). Together, they provided an in-depth review of the latest AML research presented at EHA 2026, highlighting its clinical significance and future implications.

The 2026 European Hematology Association (EHA) Annual Meeting was grandly held in Madrid, Spain. As one of the most influential academic events in the global hematology field, the application of allo-HSCT in myeloid neoplasms remains a focus of academic debate and innovation. This specialized session, chaired by Professor Anna Sureda (Catalan Institute of Oncology, Barcelona, Spain), focused on post-transplant molecular monitoring, refinement of prognostic strategies, and algorithm optimization for refractory cases in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Research teams from China, Switzerland, Sweden, Spain, and other countries shared five milestone academic reports, providing new evidence-based medical grounds for clinical precision transplantation.

At the 2026 European Hematology Association (EHA) Annual Meeting, managing the treatment burden of multiple myeloma (MM) became a core topic. As innovative therapies such as bispecific antibodies (BsAbs) and CAR-T enter clinical practice, how to reduce patient infection risks, optimize the convenience of administration, and improve quality of life while pursuing deep remission has become a major challenge for clinicians. This meeting invited Professor Joseph Mikhael from City of Hope, Professor Maria-Victoria Mateos from the University Hospital of Salamanca, and Professor Xavier Leleu from Poitiers University Hospital to conduct an in-depth discussion on "Managing the Burden of MM Treatments."

As part of its special ASCO 2026 coverage series, “China Perspectives at ASCO,” Oncology Frontier – Hematology Frontier invited leading Chinese experts to interpret the most practice-changing research presented at this year’s meeting and discuss its relevance to clinical practice in China.

The treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) remains a major clinical challenge. While CAR-T cell therapy can induce rapid and deep remissions, many patients continue to face a substantial risk of relapse. Consolidation with allogeneic hematopoietic stem cell transplantation (allo-HSCT) following CAR-T therapy has emerged as a promising curative strategy. However, evidence regarding its long-term efficacy, optimal timing, and the role of molecular biomarkers in guiding treatment decisions has remained limited.